866-997-4948(US-Canada Toll Free)

Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment (FDI) in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies

Published By :

GBI Research

Published Date : Jun 2012

Category :

Pharmaceutical

No. of Pages : 98 Pages


Emerging Pharmaceutical Market in Indonesia and Philippines 100% Foreign Direct Investment (FDI) in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies

Summary

GBI Research’s new report, “Emerging Pharmaceutical Market in Indonesia and Philippines 100% Foreign Direct Investment (FDI) in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies”, provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in Indonesia and in the Philippines. The report analyzes the overall pharma market structure in these countries, provides competitive benchmarking for the leading companies, and analyzes the M&A and strategic partnerships that shape the Indonesian and Filipino pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Indonesian pharmaceutical industry exhibited high growth after the government announced a plan to allow 100% foreign ownership of drug firms to increase overseas investment in the sector and thereby raise the volume and quality of local production. The Philippines’ pharmaceutical industry on the other hand witnessed slow growth due to a drug pricing law implemented by the government. The Indonesian pharmaceutical industry has noticeably changed since the approval of the Universally Accessible Cheaper and Quality Medicines Act that includes the Maximum Drug Retail Price (MDRP) scheme. MDRP called for a 50% price reduction for more than 100 drugs. 

Indonesia and the Philippines recently joined the ranks of the top 20 most populated countries in the world, meaning they offer huge patient populations. There has been a rise in the incidence of chronic diseases like diabetes, obesity, and cardiovascular disease. Emerging markets such as Indonesia must address the population’s rising demand for healthcare and significant unmet medical needs. 

The Philippines’ CRO market is gaining attention globally due to its favorable regulatory environment and huge patient base offered by the country’s large population. However, the Indonesian CRO market is not as favorable for drugs registration procedures, which currently take 300 days after submission to the Indonesian Food and Drug Monitoring Agency (BPOM). Indonesia and the Philippines currently account for a tiny share of the global CMO market but are set to capitalize on increasing outsourcing opportunities from western countries.

Scope

  • Overall pharma market structure in Indonesia and the Philippines
  • Indonesia and the Philippines’ pharmaceutical market characterizations, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channel and intellectual property rights
  • Indonesia and the Philippines’ CMO and CRO market analysis
  • Analysis of the leading segments within the Indonesia and Filipino pharmaceutical industries
  • Competitive benchmarking of leading companies in the pharmaceutical markets
  • Key M&A activities and strategic partnership deals that have taken place between 2004 to 2011

Reasons to buy

  • Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers of the country’s pharmaceutical market.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9

2 Emerging Pharmaceutical Market: Indonesia and the Philippines –Introduction 11

3 Emerging Pharmaceutical Market: Indonesia and the Philippines – Industry Characteristics 12
3.1 Market Size and Market Forecast 12
3.1.1 Indonesia 12
3.1.2 The Philippines 14
3.2 Market Share by Therapeutic Area 15
3.2.1 Indonesia 15
3.2.2 The Philippines 17
3.3 Market Share – Branded versus Generic Market Share 18
3.3.1 Indonesia 18
3.3.2 The Philippines 19
3.4 Top Five Pharmaceutical Companies, Market Share 20
3.4.1 Indonesia 20
3.4.2 The Philippines 26
3.5 R&D Expenditure and Innovations 32
3.5.1 Indonesia 32
3.5.2 The Philippines 32
3.6 Trends and Recent Developments in Foreign Direct Investment 33
3.6.1 Indonesia 33
3.6.2 The Philippines 33
3.7 Marketing Distribution Channel 34
3.7.1 Indonesia 34
3.7.2 The Philippines 35
3.8 PESTLE Analysis 36
3.8.1 Indonesia 36
3.8.2 The Philippines 38

4 Emerging Pharmaceutical Market: Indonesia and the Philippines – Macroeconomic Environment 41
4.1 Demographic Analysis 41
4.1.1 Population Size, Growth, and Structure 41
4.1.2 Mortality Rate 45
4.1.3 Population Ageing and Health 45
4.2 GDP 46
4.2.1 Indonesia 46
4.2.2 The Philippines 47
4.3 Per Capita Income 48
4.3.1 Indonesia 48
4.3.2 The Philippines 49
4.4 Income Status 50
4.4.1 Indonesia 50
4.4.2 The Philippines 50
4.5 Healthcare Expenditure 51
4.5.1 Context 51
4.6 Healthcare Infrastructure 52
4.6.1 Context 52

5 Emerging Pharmaceutical Market: Indonesia and The Philippines – Healthcare Regulation 53
5.1 Pharmaceutical Regulation in Indonesia and the Philippines 53
5.1.1 Healthcare System Structure 53
5.2 Drug Approval Process 55
5.2.1 Indonesia 55
5.2.2 The Philippines 56
5.3 Patents and Generics (IPR) 57
5.3.1 Context 57
5.3.2 Analytical Framework 58
5.4 Health Insurance Coverage 59
5.4.1 Indonesia 59
5.4.2 The Philippines 59
5.5 Clinical Trials 60
5.5.1 Context 60
5.5.2 Analytical Framework 61
5.6 Pricing and Reimbursement 62
5.6.1 Context 62

6 Emerging Pharmaceutical Market: Indonesia and the Philippines – Industry Trends 64
6.1 Deals by Type 64
6.1.1 Indonesia 64
6.1.2 The Philippines 65
6.2 Mergers and Acquisitions 66
6.2.1 Deals by Year 66
6.2.2 Deal by Value 68
6.2.3 Indonesia and the Philippines – Top Five M&A Deals 70
6.3 Licensing Agreements 72
6.3.1 Deals by Year 72
6.3.2 Deals by Value 74
6.3.3 Indonesia and the Philippines – Top Five Licensing Deals 76
6.4 Co-Development Deals 79
6.4.1 By Year 79
6.4.2 By Value 81
6.4.3 Indonesia and the Philippines – Top Five Co-Development Deals 83

7 Emerging Pharmaceutical Market: Indonesia and The Philippines – Service Industries – CMO, CRO 86
7.1 Clinical Research Organization (CRO) 86
7.1.1 Indonesia CRO PEST Analysis 86
7.1.2 Philippines CRO PEST Analysis 87
7.2 Contract Manufacturing Organization (CMO) 87
7.2.1 Indonesia CMO PEST Analysis 87
7.2.2 The Philippines CMO PEST Analysis 88

8 Appendix 89
8.1 Market Definitions 89
8.2 Abbreviations 89
8.3 Sources 90
8.4 Research Methodology 90
8.4.1 Industry Characteristics 91
8.4.2 Demographic Analysis 91
8.4.3 Healthcare Regulation 91
8.4.4 Industry Trends 91
8.4.5 Service Industries – CMO, CRO 91
8.5 Contact Us 91
8.6 Disclaimer 92

List of Table


Table 1: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Pharmaceutical Market Size ($bn), 2004-2011 12
Table 2: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Pharmaceutical Market Size ($bn), 2011-2018 12
Table 3: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Pharmaceutical Market Size ($bn), 2004-2011 14
Table 4: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Pharmaceutical Market Size ($bn), 2011-2018 14
Table 5: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Demographic Analysis, Population Size, July 2011 41
Table 6: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Demographic Analysis, Population Growth Rate (%), 2002-2011 42
Table 7: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Age Structure (%), 2002-2018 43
Table 8: Emerging Pharmaceutical Market, The Philippines, Macroeconomic Environment, Demographic Analysis, Population Growth Rate (%), 2002-2011 44
Table 9: Emerging Pharmaceutical Market: Indonesia and The Philippines, Macroeconomic Environment, Mortality Rate Analysis (deaths/1,000 population), July 2011 45
Table 10: Emerging Pharmaceutical Market, Indonesia, Macroeconomic Environment, Age Structure, 2011 est. 45
Table 11: Emerging Pharmaceutical Market, The Philippines, Macroeconomic Environment, Age Structure, 2011 est. 45
Table 12: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, GDP Growth Rate (Annual %), 2002-2011 46
Table 13: Emerging Pharmaceutical Market: The Philippines, Macroeconomic Environment, GDP Growth Rate (Annual %), 2002-2011 47
Table 14: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, GDP per capita (PPP), $, 2002-2011 48
Table 15: Emerging Pharmaceutical Market: The Philippines, Macroeconomic Environment, GDP per capita (PPP), $, 2002-2011 49
Table 16: Emerging Pharmaceutical Market, Indonesia, Macroeconomic Environment, Income Status, 2010 50
Table 17: Emerging Pharmaceutical Market, The Philippines, Macroeconomic Environment, Income Status, 2010 50
Table 18: Emerging Pharmaceutical Market: Indonesia and the Philippines, Indonesia, Macroeconomic Environment, Healthcare Expenditure (%), 2004-2010 51
Table 19: Emerging Pharmaceutical Market: Indonesia and the Philippines, the Philippines, Macroeconomic Environment, Healthcare Expenditure (%), 2004-2010 51
Table 20: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Healthcare Infrastructure, Hospital bed density (beds/1,000 population), January 2011 52
Table 21: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Healthcare Infrastructure, Physicians density (physicians/1,000 population), January 2011 52
Table 22: Emerging Pharmaceutical Market, Indonesia, Healthcare Regulation, Health Insurance Coverage, 2011 59
Table 23: Emerging Pharmaceutical Market, Indonesia, Healthcare Regulation, Number of Clinical Trials, 1997-2011 60
Table 24: Emerging Pharmaceutical Market, The Philippines, Healthcare Regulation, Number of Clinical Trials, 2002-2011 61
Table 25: Emerging Pharmaceutical Market, Healthcare Regulation, Total Number of Clinical Trials Until 2012 61
Table 26: Emerging Pharmaceutical Market, The Philippines, Healthcare Regulation, Drug Pricing, 2008-2010 62
Table 27: Emerging Pharmaceutical Market: Indonesia, Industry Trends, Deals by Type, 2004-2011 64
Table 28: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Deals by Type, 2004-2011 65
Table 29: Emerging Pharmaceutical Market, Indonesia, Industry Trends, M&A Deals by Year, 2004-2011 66
Table 30: Emerging Pharmaceutical Market, The Philippines, Industry Trends, M&A Deals by Year, 2004-2011 67
Table 31: Emerging Pharmaceutical Market, Indonesia, Industry Trends, M&A Deals by Value, 2004-2011 68
Table 32: Emerging Pharmaceutical Market, The Philippines, Industry Trends, M&A Deals by Year, 2004-2011 69
Table 33: Emerging Pharmaceutical Market: Indonesia and the Philippines, Industry Trends, Top Five M&A Deals by Value, 2006-2011 70
Table 34: Emerging Pharmaceutical Market: Indonesia, Industry Trends, Licensing Deals by Year, 2004-2011 72
Table 35: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Licensing Deals by Year, 2004-2011 73
Table 36: Emerging Pharmaceutical Market: Indonesia, Industry Trends, Licensing Deals by Value, 2004-2011 74
Table 37: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Licensing Deals by Value, 2004-2011 75
Table 38: Emerging Pharmaceutical Market: Indonesia and the Philippines, Industry Trends, Top Five Licensing Deals by Value, 2006-2011 76
Table 39: Emerging Pharmaceutical Market, Indonesia, Industry Trends, Co-Development Deals by Year, 2004-2011 79
Table 40: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Co-Development Deals by Year, 2004-2011 80
Table 41: Emerging Pharmaceutical Market, Indonesia, Industry Trends, Co-Development Deals by Value, 2004-2011 81
Table 42: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Co-Development Deals by Value, 2004-2011 82
Table 43: Emerging Pharmaceutical Market: Indonesia and The Philippines, Industry Trends, Top Five Co-Development Deals by Value, 2006-2011 83

List of Chart


Figure 1: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Pharmaceutical Market Size ($bn), 2004-2018 12
Figure 2: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Pharmaceutical Market Size ($bn), 2004-2018 14
Figure 3: Emerging Pharmaceutical Market, Industry Characteristics, Patient Population, 2009, 2010 15
Figure 4: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Market Segmentation by Therapeutic Class (%), 2011 16
Figure 5: Emerging Pharmaceutical Market, The Philippines, Industry Characteristics, Prevalence (%), 2011 17
Figure 6: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Branded and Generic Drugs Market Share (%), 2011 18
Figure 7: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, OTC and Prescription Drugs Market Share (%), 2011 19
Figure 8: Emerging Pharmaceutical Market, The Philippines, Industry Characteristics, OTC and Prescription Drugs Market Share (%), 2011 19
Figure 9: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Top Five Pharmaceutical Companies Market Share (%), 2011 20
Figure 10: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, PT. Kalbe Farma Tbk SWOT Analysis, 2011 21
Figure 11: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Dexa Medica SWOT Analysis, 2011 22
Figure 12: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Sanbe Farma SWOT Analysis, 2011 23
Figure 13: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, PT. SOHO Industri Pharmasi SWOT Analysis, 2011 24
Figure 14: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, PT Tempo Scan Pacific Tbk. SWOT Analysis, 2011 25
Figure 15: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Companies Market Share (%), 2011 26
Figure 16: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, UNILAB SWOT Analysis, 2011 27
Figure 17: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, GSK SWOT Analysis, 2011 28
Figure 18: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Euro-Med Lab SWOT Analysis, 2011 29
Figure 19: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Pfizer Inc SWOT Analysis, 2011 30
Figure 20: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Bristol Myers Squibb SWOT Analysis, 2011 31
Figure 21: Emerging Pharmaceutical Market: Indonesia, Industry Characteristics, Marketing Distribution Channel (%), 2011 34
Figure 22: Emerging Pharmaceutical Market: The Philippines, Industry Characteristics, Marketing Distribution Channel (%), 2008 35
Figure 23: Emerging Pharmaceutical Market, Indonesia, Industry Characteristics, Indonesia Pharmaceutical Market PESTLE Analysis, 2011 36
Figure 24: Emerging Pharmaceutical Market, The Philippines, Industry Characteristics, The Philippines Pharmaceutical Market PESTLE Analysis, 2011 38
Figure 25: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Demographic Analysis, Population Growth Rate (%), 2002-2011 42
Figure 26: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, Age Structure (%), 2002-2018 43
Figure 27: Emerging Pharmaceutical Market, The Philippines, Macroeconomic Environment, Demographic Analysis, Population Growth Rate (%), 2002-2011 44
Figure 28: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, GDP Growth Rate (Annual %), 2002-2011 46
Figure 29: Emerging Pharmaceutical Market: The Philippines, Macroeconomic Environment, GDP Growth Rate (Annual %), 2002-2011 47
Figure 30: Emerging Pharmaceutical Market: Indonesia, Macroeconomic Environment, GDP per capita (PPP), $, 2002-2011 48
Figure 31: Emerging Pharmaceutical Market: The Philippines, Macroeconomic Environment, GDP per capita (PPP), $, 2002-2011 49
Figure 32: Emerging Pharmaceutical Market: Indonesia, Healthcare Regulation, Organizational Structure of the Public Healthcare System, 2011 53
Figure 33: Emerging Pharmaceutical Market: The Philippines, Healthcare Regulation, Healthcare Flow-of-Funds, 2011 54
Figure 34: Emerging Pharmaceutical Market, Indonesia, Healthcare Regulation, Drug Approval Process, 2011 55
Figure 35: Emerging Pharmaceutical Market, Healthcare Regulation, IPR, Counterfeit Incident Trends by Region, 2010 58
Figure 36: Emerging Pharmaceutical Market, The Philippines, Healthcare Regulation, Health Insurance Coverage, 2010 59
Figure 37: Emerging Pharmaceutical Market: Indonesia, Industry Trends, Deals by Type (%), 2004-2011 64
Figure 38: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Deals by Type (%), 2004-2011 65
Figure 39: Emerging Pharmaceutical Market, Indonesia, Industry Trends, M&A Deals by Year, 2004-2011 66
Figure 40: Emerging Pharmaceutical Market, The Philippines, Industry Trends, M&A Deals by Year, 2004-2011 67
Figure 41: Emerging Pharmaceutical Market, Indonesia, Industry Trends, M&A Deals by Value (%), 2004-2011 68
Figure 42: Emerging Pharmaceutical Market, The Philippines, Industry Trends, M&A Deals by Year (%), 2004-2011 69
Figure 43: Emerging Pharmaceutical Market: Indonesia, Industry Trends, Licensing Deals by Year, 2004-2011 72
Figure 44: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Licensing Deals by Year, 2004-2011 73
Figure 45: Emerging Pharmaceutical Market: Indonesia, Industry Trends, Licensing Deals by Value (%), 2004-2011 74
Figure 46: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Licensing Deals by Value (%), 2004-2011 75
Figure 47: Emerging Pharmaceutical Market, Indonesia, Industry Trends, Co-Development Deals by Year, 2004-2011 79
Figure 48: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Co-Development Deals by Year, 2004-2011 80
Figure 49: Emerging Pharmaceutical Market, Indonesia, Industry Trends, Co-Development Deals by Value (%), 2004-2011 81
Figure 50: Emerging Pharmaceutical Market, The Philippines, Industry Trends, Co-Development Deals by Value (%), 2004-2011 82
Figure 51: Emerging Pharmaceutical Market, Indonesia, Service Industry, Emerging Markets CRO Analysis, 2010 86
Figure 52: Emerging Pharmaceutical Market, Indonesia, Service Industry, CRO Market PEST Analysis, 2011 86
Figure 53: Emerging Pharmaceutical Market, The Philippines, Service Industry, CRO Market PEST Analysis, 2011 87
Figure 54: Emerging Pharmaceutical Market, Indonesia, Service Industry, CMO Market PEST Analysis, 2011 87
Figure 55: Emerging Pharmaceutical Market, The Philippines, Service Industry, CMO Market PEST Analysis, 2011 88

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Noscapine Base Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    Noscapine is an alkaloid obtained from poppy plants. It is used in the pharmaceutical industry as an anti-tussive or cough suppressing agent. Noscapine does not possess pain killing properties, however, it is known to alleviate cough. It is also known as narcotine, anarcotine, nectodon, nospen and opiane among others. Noscapine is used as an over-the-counter cough suppressant and is known to be a sleep inducer. It has anti-inflammatory effe...

  • E-Clinical Trial Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    E-clinical trial solutions are a combination of technology, products and services that work together to automate and manage clinical trials. This term is used to refer to electronic systems that are used for conducting or automating the management of clinical trials and minimizing human errors.Conducting clinical trials for a novel drug requires efficient management of large amount of essential data with real-time analysis.Such management...

  • Hydrocodone Bitartrate Market - Global Industry Analysis, Size, Share, Trends and Forecast 2014 - 2020

    Hydrocodone bitartrate is often used to relieve severe ongoing pain. It belongs to the narcotic (opiate) analgesic class of drugs. It affects the functioning of the brain by altering how the body responds to pain. Hydrocodone Bitartrate is generally prescribed for oral ingestion as narcotic aanalgesic and antitussive. It is often given in combination with ibuprofen or acetaminophen. The Administrative Controlled Substance Code Number (ACSC...